Glenmark Pharmaceuticals
Glenmark Pharmaceuticals
Shareholder Return: 3-year average, Sales Growth: 3-year Compounded Annual Growth Rate, Return On Equity: 3-year Return on Equity.
At a Glance
-
Shareholder Return161%
-
Sales Growth18%
-
Return on Equity20 %
Why Super 50
It counts itself among the world's top 80 pharmaceutical and biotech companies in terms of revenue. Having built a sizeable presence across highly regulated global markets, the company is betting big on drug discovery. Its pipeline of drugs for treatment of chronic and debilitating diseases has the potential to garner sales of $1 billion to $3 billion each. No surprises then that its IPO in 2000 was oversubscribed 65 times.
